tiprankstipranks
Rallybio reports Q3 EPS (26c), consensus (35c)
PremiumThe FlyRallybio reports Q3 EPS (26c), consensus (35c)
2M ago
Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved
Premium
The Fly
Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved
2M ago
Rallybio participates in a conference call with JPMorgan
Premium
The Fly
Rallybio participates in a conference call with JPMorgan
3M ago
Rallybio Executive Chairman Announces Plans to Step Down
PremiumCompany AnnouncementsRallybio Executive Chairman Announces Plans to Step Down
5M ago
Rallybio reports results from epidemiological analysis evaluating FNAIT risk
Premium
The Fly
Rallybio reports results from epidemiological analysis evaluating FNAIT risk
6M ago
Rallybio downgraded to Neutral from Overweight at JPMorgan
Premium
The Fly
Rallybio downgraded to Neutral from Overweight at JPMorgan
7M ago
Rallybio to partner with J&J on soultions to reduce risk of FNAIT
PremiumThe FlyRallybio to partner with J&J on soultions to reduce risk of FNAIT
9M ago
Rallybio price target lowered to $9 from $12 at H.C. Wainwright
Premium
The Fly
Rallybio price target lowered to $9 from $12 at H.C. Wainwright
9M ago
Rallybio reports Q4 EPS (50c), consensus (46c)
Premium
The Fly
Rallybio reports Q4 EPS (50c), consensus (46c)
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100